Immutep shares are trading lower. The company announced efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD's anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients.
Portfolio Pulse from Benzinga Newsdesk
Immutep shares declined following the announcement of efficacy and safety results from the TACTI-003 Phase IIb trial. The trial evaluated eftilagimod alpha with KEYTRUDA for treating head and neck squamous cell carcinoma.
September 16, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Immutep's stock is trading lower due to the announcement of trial results for eftilagimod alpha with KEYTRUDA. The market may perceive the results as less favorable, impacting investor sentiment.
The decline in Immutep's stock price suggests that investors may have been disappointed with the trial results. The combination therapy's performance in the trial is crucial for Immutep's future prospects, hence the significant impact on the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90